|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-4-13
|
|
pubmed:abstractText |
Oxaliplatin in combination with infusional 5-fluorouracil/leucovorin (FOLFOX) have emerged as the standard of care in the therapy of advanced-stage colorectal cancer. Sensory neurotoxicity is its dose-limiting toxicity. We decided to use Ca and Mg for prevention of oxaliplatin-related neurotoxicity with reference to the report of Gamelin et al.
|
|
pubmed:language |
jpn
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0385-0684
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
579-81
|
|
pubmed:meshHeading |
pubmed-meshheading:17431344-Aged,
pubmed-meshheading:17431344-Aged, 80 and over,
pubmed-meshheading:17431344-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17431344-Calcium,
pubmed-meshheading:17431344-Colorectal Neoplasms,
pubmed-meshheading:17431344-Female,
pubmed-meshheading:17431344-Fluorouracil,
pubmed-meshheading:17431344-Humans,
pubmed-meshheading:17431344-Leucovorin,
pubmed-meshheading:17431344-Magnesium,
pubmed-meshheading:17431344-Male,
pubmed-meshheading:17431344-Middle Aged,
pubmed-meshheading:17431344-Neurotoxicity Syndromes,
pubmed-meshheading:17431344-Organoplatinum Compounds,
pubmed-meshheading:17431344-Peripheral Nervous System Diseases
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
[Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
|
|
pubmed:affiliation |
Division of Surgery, Nakadori General Hospital.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
